Medicus Pharma submits optimized teverelix protocol to FDA for advanced prostate cancer program
MDCX•Medicus Pharma submitted an optimized teverelix registrational protocol to the FDA and anticipates completing GMP manufacturing and study readiness before year-end 2026; it intends to seek a strategic partner or out-license the program.
1. Protocol submission
Medicus Pharma submitted an optimized teverelix registrational protocol to the FDA for its advanced prostate cancer program. The company anticipates completing GMP manufacturing and study readiness before year-end 2026, and intends to seek a strategic partner or out-license the program.
